Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
May 23, 2016
HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up
Christian Jackisch, Roberto Hegg, Daniil Stroyakovskiy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2018
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)
Michael Untch, Gunter von Minckwitz, Bernd Gerber, et al.
Annals of Surgical Oncology
|
April 18, 2014
Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44)
Bernd Gerber, Gunter von Minckwitz, Holger Eidtmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 11, 2025
Atezolizumab Monotherapy Window Preceding Combined Neoadjuvant Chemotherapy and Immune Therapy in Triple-Negative Breast Cancer-The neoMono Trial
Hans-Christian Kolberg, Johannes Schumacher, Ramona Erber, et al.
International Journal of Molecular Medicine
|
November 3, 2010
Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer
Heidrun Gevensleben, Uwe-Jochen Göhring, Reinhard Büttner, et al.
Plos One
|
December 7, 2013
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial
Yasmin Issa-Nummer, Silvia Darb-Esfahani, Sibylle Loibl, et al.
The New England Journal of Medicine
|
January 27, 2012
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
Gunter von Minckwitz, Holger Eidtmann, Mahdi Rezai, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 15, 2023
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer
Paolo Nuciforo, John Townend, Martine J Piccart, et al.
Lancet (London, England)
|
January 20, 2012
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
José Baselga, Ian Bradbury, Holger Eidtmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 22, 2020
Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial
Suzette Delaloge, Martine Piccart, Emiel Rutgers, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
European Journal of Cancer (Oxford, England : 1990)
|
May 23, 2016
HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up
Christian Jackisch, Roberto Hegg, Daniil Stroyakovskiy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2018
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)
Michael Untch, Gunter von Minckwitz, Bernd Gerber, et al.
Annals of Surgical Oncology
|
April 18, 2014
Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44)
Bernd Gerber, Gunter von Minckwitz, Holger Eidtmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 11, 2025
Atezolizumab Monotherapy Window Preceding Combined Neoadjuvant Chemotherapy and Immune Therapy in Triple-Negative Breast Cancer-The neoMono Trial
Hans-Christian Kolberg, Johannes Schumacher, Ramona Erber, et al.
International Journal of Molecular Medicine
|
November 3, 2010
Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer
Heidrun Gevensleben, Uwe-Jochen Göhring, Reinhard Büttner, et al.
Plos One
|
December 7, 2013
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial
Yasmin Issa-Nummer, Silvia Darb-Esfahani, Sibylle Loibl, et al.
The New England Journal of Medicine
|
January 27, 2012
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
Gunter von Minckwitz, Holger Eidtmann, Mahdi Rezai, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 15, 2023
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer
Paolo Nuciforo, John Townend, Martine J Piccart, et al.
Lancet (London, England)
|
January 20, 2012
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
José Baselga, Ian Bradbury, Holger Eidtmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 22, 2020
Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial
Suzette Delaloge, Martine Piccart, Emiel Rutgers, et al.
Page
of 3